Free Trial

Wells Fargo & Company's Rating of BridgeBio Pharma on 8/11/2026

On August 11, 2026, Wells Fargo & Company updated its outlook on BridgeBio Pharma (NASDAQ:BBIO) with the action "Boost Price Target", setting a price target of $102.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Wells Fargo & Company

DateCompanyAction
10/15/2026
Bank of America Corporation stock logo
BAC
Bank of America
Lower Price Target
10/15/2026
Pershing Square Inc. stock logo
PS
Pershing Square
Lower Price Target
10/15/2026
BlackRock stock logo
BLK
BlackRock
Boost Price Target
10/15/2026
IMAX Corporation stock logo
IMAX
IMAX
Boost Price Target
10/15/2026
The Progressive Corporation stock logo
PGR
Progressive
Lower Price Target
10/15/2026
Morgan Stanley stock logo
MS
Morgan Stanley
Lower Price Target
More Ratings From Wells Fargo & Company